NKTR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

10.43M

-64.24%

-2.423

-638.41%

10.10M

-3.45%

-2.150

-40.29%

9.98M

-10.71%

-2.373

-19.55%

Estimates Revision

The market is revising Upward the revenue expectations for Nektar Therapeutics (NKTR) for FY2025, with the revenue forecasts being adjusted by 2.13% over the past three months. During the same period, the stock price has changed by -26.92%.

Revenue Estimates for FY2025

Revise Upward

+2.13%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-12.79%

In Past 3 Month

Stock Price

Go Down

-26.92%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast NKTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTR is 93.86 USD with a low forecast of 30.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

30.00

Averages

93.86

High

120.00

Current: 0.000

Low

30.00

Averages

93.86

High

120.00

Oppenheimer

Jay Olson

Outperform

maintain

$98 -> $115

2025-12-16

Reason

Oppenheimer

Jay Olson

Price Target

$98 -> $115

2025-12-16

maintain

Outperform

Reason

Oppenheimer analyst Jay Olson raised the firm's price target on Nektar to $115 from $98 and keeps an Outperform rating on the shares after the company provided updates on the results from its Phase 2b REZOLVE-AA study evaluating rezpeg in alopecia areata. While the study missed the primary endpoint "by a whisker," excluding four patients with eligibility violations suggests a nominal statistical significance for both doses, the analyst tells investors in a research note. Oppenheimer sees "compelling activity" for rezpeg in alopecia areata. It upped the probability of success for the indication to 50%. Nektar in morning trading is down 8% to $48.88.

H.C. Wainwright

Buy

maintain

$120 -> $135

2025-12-16

Reason

H.C. Wainwright

Price Target

$120 -> $135

2025-12-16

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Nektar to $135 from $120 and keeps a Buy rating on the shares after the company reported "encouraging" topline results from the 36-week induction phase of its Phase 2b REZOLVE-AA study of rezpeg in alopecia areata. Following the data, the firm is increasing its view of the odds of launch for rezpeg in AA to 25%, from 20%, and it projects the drug to generate risk-adjusted revenues of $59M in 2030, growing to $380M by 2035.

Citi

NULL

Buy

initiated

$102

2025-11-26

Reason

Citi

Price Target

$102

2025-11-26

initiated

NULL

Buy

Reason

Citi initiated coverage of Nektar with a Buy rating and $102 price target. Citi also opened a "positive 90-day catalyst watch" on Nektar ahead of the Phase 2b alopecia areata data expected in December. The firm believes data for rezpegaldesleukin in atopic dermatitis "look competitive" in crowded field. It sees an "asymmetrical upside" opportunity for the shares into the December readout.

Jefferies

Buy

upgrade

$99 -> $121

2025-11-26

Reason

Jefferies

Price Target

$99 -> $121

2025-11-26

upgrade

Buy

Reason

Jefferies raised the firm's price target on Nektar to $121 from $99 and keeps a Buy rating on the shares. With "relatively low expectations" going into Nektar's Rezpeg reporting Phase 2b topline data in Alopecia Areata in December, the firm sees "significant upside potential and limited downside" given Rezpeg's novel mechanism of action, clean safety profile and durability potential, the analyst tells investors. The firm is adding AA to its model with 20% odds of success and about $300M in estimated peak sales.

Jefferies

Roger Song

Buy

maintain

$69 -> $99

2025-09-18

Reason

Jefferies

Roger Song

Price Target

$69 -> $99

2025-09-18

maintain

Buy

Reason

Jefferies analyst Roger Song raised the firm's price target on Nektar to $99 from $69 and keeps a Buy rating on the shares after the company announced data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin. The positive patient-reported outcome assessments add further support for rezpegaldesleukin's benefit in atopic dermatitis and complimented the efficacy data reported in June, the analyst tells investors in a research note. Jefferies upped the drug's probability of success to 55% from 45%.

Oppenheimer

Outperform

upgrade

$90 -> $98

2025-08-08

Reason

Oppenheimer

Price Target

$90 -> $98

2025-08-08

upgrade

Outperform

Reason

Oppenheimer raised the firm's price target on Nektar to $98 from $90 and keeps an Outperform rating on the shares following quarterly results. The firm notes Q2 marks an important milestone for Nektar, as the company reported positive topline results from the Phase 2b REZOLVE-AD study of rezpeg in atopic dermatitis. Oppenheimer anticipates additional updates in the coming months, including data presentation in the second half of the year at a medical conference; alopecia areata topline results in December; and maintenance data from REZOLVE-AD in Q1 2026.

Valuation Metrics

The current forward P/E ratio for Nektar Therapeutics (NKTR.O) is -4.58, compared to its 5-year average forward P/E of -2.86. For a more detailed relative valuation and DCF analysis to assess Nektar Therapeutics 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.86

Current PE

-4.58

Overvalued PE

-0.77

Undervalued PE

-4.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.12

Current EV/EBITDA

-4.23

Overvalued EV/EBITDA

0.12

Undervalued EV/EBITDA

-4.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

10.71

Current PS

21.90

Overvalued PS

21.60

Undervalued PS

-0.18

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 1229.84% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NKTR News & Events

Events Timeline

No data

News

9.5

01-05Fool

Nektar Therapeutics Faces Risks as Madrigal Pharmaceuticals Reports $287.3M in Sales

9.5

01-05NASDAQ.COM

Nektar's Drug Uncertainty vs. Madrigal's Strong Sales Performance

7.0

01-01PRnewswire

Nektar Therapeutics Stock Drops 7.77% Following Phase 2b Trial Failure

People Also Watch

Frequently Asked Questions

What is Nektar Therapeutics (NKTR) stock price today?

The current price of NKTR is 39.71 USD — it has decreased -4.17 % in the last trading day.

What is Nektar Therapeutics (NKTR)'s business?

Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

What is the price predicton of NKTR Stock?

What is Nektar Therapeutics (NKTR)'s revenue for the last quarter?

Nektar Therapeutics revenue for the last quarter amounts to 11.79M USD, decreased -51.13 % YoY.

What is Nektar Therapeutics (NKTR)'s earnings per share (EPS) for the last quarter?

Nektar Therapeutics. EPS for the last quarter amounts to -1.87 USD, decreased -29.70 % YoY.

What changes have occurred in the market's expectations for Nektar Therapeutics (NKTR)'s fundamentals?

How many employees does Nektar Therapeutics (NKTR). have?

Nektar Therapeutics (NKTR) has 61 emplpoyees as of January 10 2026.

What is Nektar Therapeutics (NKTR) market cap?

Today NKTR has the market capitalization of 807.76M USD.